Matthew Hill, founder and CEO of Elegen joins a Drug Discovery World webinar to discuss the DNA supply bottleneck in mRNA drug development workflows and how Elegen uses an innovative cell-free DNA synthesis platform to supply biopharma companies rapidly and reliably with long, complex, NGS-verified, dsDNA. With ENFINIA DNA, scientists can eliminate cell based cloning from the mRNA therapy development processes bringing new therapies to market faster.